SSTR2 and paraganglioma: Beneficial outcomes and low toxicity of PRRT have now been described in NET arising from other primary sites 2, of higher grade 3 and in other diseases that express the therapeutic target, the somatostatin 2 receptor (SSTR2), including phaeochromocytoma/paraganglioma 4-6 and neuroblastoma 7.